DOPPS Practice Monitor to DOPPS.org
 
Last Data Update:  April 2018 (data through February 2018)
Featured Data
Browse All Data
News & Publications
About DPM
 Download Quality of Life Data
1.  Filter By:    
2.  Choose a category:
3.  Browse graphics:
Skip Navigation Links.
Expand Facility profit status<input id='gid' type=hidden class='gidclass' value=''><input id='c' type=hidden class='cclass5p' value='5p'><input id='p' type=hidden class='pclass' value=''>Facility profit status
Click to Enlarge

Sample sizes and statistics for figure above   -   Understanding the DPM Figures   -   Share

Sample sizes and statistics for figure above   -   Understanding the DPM Figures

  

SHARE





  

Sign up for DPM updates
Copyright © 2019, Arbor Research Collaborative for Health.  | 

Privacy Policy | Feedback?
DOPPS Practice Monitor

  • Featured Data
  • Browse All Data
  • News and Publications
  • About DPM
  • National sample
    • Demographics
      • Age, categories
      • Age, continuous
      • Time on dialysis, categories
      • Time on dialysis, continuous
      • Gender
      • Race
      • Ethnicity
      • Body-mass index, categories
      • Body-mass index, continuous
    • Diabetes/Cardiovascular
      • Diabetes as cause of ESRD
      • Diabetes at study entry
      • HbA1c (most recent)
        • Categories
        • Continuous
      • HbA1c (3 month average)
        • Categories
        • Continuous
      • HbA1c measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • Pre-dialysis systolic blood pressure, categories
      • Pre-dialysis systolic blood pressure, continuous
      • Aspirin use
      • Beta blocker use
      • Calcium channel blocker use
      • Renin-angiotensin system (RAS) inhibitor use
      • Renin-angiotensin system (RAS) inhibitor combination
      • Statin use
    • Anemia
      • Hemoglobin (most recent)
        • All patients, categories
        • All patients, continuous
        • ESA-treated pts, categories
        • ESA-treated pts, continuous
      • Hemoglobin (3 month average)
        • All patients, categories
        • All patients, continuous
        • ESA-treated pts, categories
        • ESA-treated pts, continuous
      • Erythropoiesis Stimulating Agent (ESA) use
        • Use in last 1 month
        • Use in last 3 months
        • Route of administration
        • ESA type
      • Weekly IV epoetin dose received
        • 30 day average, categories
        • 30 day average, continuous
        • 90 day average, categories
        • 90 day average, continuous
      • IV iron use
        • Use in last 1 month
        • Use in last 3 months
        • IV iron type
      • Monthly IV iron dose received
        • 30 day average, categories
        • 30 day average, continuous
        • 90 day average, categories
        • 90 day average, continuous
      • Serum ferritin (most recent)
        • Categories
        • Continuous
      • Serum ferritin (3 month average)
        • Categories
        • Continuous
      • Ferritin measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • Transferrin saturation (most recent)
        • Categories
        • Continuous
      • Transferrin saturation (3 month average)
        • Categories
        • Continuous
    • Potassium
      • Serum potassium (most recent)
        • Categories
        • Continuous
      • Serum potassium (3 month average)
        • Categories
        • Continuous
      • Serum potassium measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • Potassium binder use
    • Dialysis Prescription and Dose
      • Achieved dialysis session length, categories
      • Achieved dialysis session length, continuous
      • Intra-dialytic weight loss (%)
      • Prescribed blood flow rate, categories
      • Prescribed blood flow rate, continuous
      • Prescribed dialysis sessions per week
      • Single-pool Kt/V, categories
      • Single-pool Kt/V, continuous
      • Urea reduction ratio >=65%
      • Ultrafiltration rate, categories
      • Ultrafiltration rate, continuous
    • Mineral and Bone Disorder
      • IV vitamin D analog use
        • Use in last 1 month
        • Use in last 3 months
        • IV vitamin D type
        • Use with cinacalcet
      • Weekly IV vitamin D analog dose received
        • 30 day average, categories
        • 30 day average, continuous
        • 90 day average, categories
        • 90 day average, continuous
      • Oral vitamin D use, last 3 months
      • Vitamin D analog use
        • Use in last 3 months
        • Vitamin D type
        • Route of administration
      • Calcimimetics use
        • Cinacalcet use, last 1 month
        • Cinacalcet use, last 3 months
        • Cinacalcet use with vitamin D
      • Serum calcium (most recent)
        • Albumin-corrected, categories
        • Albumin-corrected, continuous
        • Total, categories
        • Total, continuous
      • Serum calcium (3 month average)
        • Albumin-corrected, categories
        • Albumin-corrected, continuous
        • Total, categories
        • Total, continuous
      • Serum phosphorus (most recent)
        • Categories
        • Continuous
      • Serum phosphorus (3 month average)
        • Categories
        • Continuous
      • Phosphate binder use
        • Use in last 1 month
        • Use in last 3 months
        • Phosphate binder type
        • Al- or Mg-containing use in last 3 months
        • Fe-containing use in last 3 months
      • Serum PTH (most recent)
        • Categories
        • Continuous
      • Serum PTH (3 month average)
        • Categories
        • Continuous
      • PTH measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • MBD control
        • Number of MBD markers out of range
        • Combinations, 2 MBD markers out of range
    • Nutrition
      • Serum albumin (most recent), categories
      • Serum albumin (most recent), continuous
      • Serum albumin (3 month average), categories
      • Serum albumin (3 month average), continuous
      • Serum creatinine (most recent), categories
      • Serum creatinine (most recent), continuous
      • Serum creatinine (3 month average), categories
      • Serum creatinine (3 month average), continuous
      • Normalized PCR, categories
      • Normalized PCR, continuous
    • Vascular Access
      • Vascular access in use
    • Medicare Transfusions
      • Percent ESRD beneficiaries with claim (1 month)
      • Facility percent ESRD beneficiaries with claim (1 month)
      • Facility percent ESRD beneficiaries with claim (6 months)
    • Medicare Hospitalizations
      • Percent ESRD beneficiaries with claim (1 month)
      • Facility percent ESRD beneficiaries with claim (1 month)
      • Facility percent ESRD beneficiaries with claim (6 months)
  • Rural/Non-rural facilities
    • Demographics
      • Age, categories
      • Age, continuous
      • Time on dialysis, categories
      • Time on dialysis, continuous
      • Gender
      • Race
      • Ethnicity
      • Body-mass index, categories
      • Body-mass index, continuous
    • Diabetes/Cardiovascular
      • HbA1c (most recent)
        • Categories
        • Continuous
      • HbA1c (3 month average)
        • Categories
        • Continuous
      • HbA1c measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • Pre-dialysis systolic blood pressure, categories
      • Pre-dialysis systolic blood pressure, continuous
      • Aspirin use
      • Beta blocker use
      • Calcium channel blocker use
      • Renin-angiotensin system (RAS) inhibitor use
      • Renin-angiotensin system (RAS) inhibitor combination
      • Statin use
    • Anemia
      • Hemoglobin (most recent)
        • All patients, categories
        • All patients, continuous
        • ESA-treated pts, categories
        • ESA-treated pts, continuous
      • Hemoglobin (3 month average)
        • All patients, categories
        • All patients, continuous
        • ESA-treated pts, categories
        • ESA-treated pts, continuous
      • Erythropoiesis Stimulating Agent (ESA) use
        • Use in last 1 month
        • Use in last 3 months
        • Route of administration
        • ESA type
      • Weekly IV epoetin dose received
        • 30 day average, categories
        • 30 day average, continuous
        • 90 day average, categories
        • 90 day average, continuous
      • IV iron use
        • Use in last 1 month
        • Use in last 3 months
        • IV iron type
      • Monthly IV iron dose received
        • 30 day average, categories
        • 30 day average, continuous
        • 90 day average, categories
        • 90 day average, continuous
      • Serum ferritin (most recent)
        • Categories
        • Continuous
      • Serum ferritin (3 month average)
        • Categories
        • Continuous
      • Ferritin measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • Transferrin saturation (most recent)
        • Categories
        • Continuous
      • Transferrin saturation (3 month average)
        • Categories
        • Continuous
    • Potassium
      • Serum potassium (most recent)
        • Categories
        • Continuous
      • Serum potassium (3 month average)
        • Categories
        • Continuous
      • Serum potassium measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • Potassium binder use
    • Dialysis Prescription and Dose
      • Achieved dialysis session length, categories
      • Achieved dialysis session length, continuous
      • Intra-dialytic weight loss (%)
      • Prescribed blood flow rate, categories
      • Prescribed blood flow rate, continuous
      • Prescribed dialysis sessions per week
      • Single-pool Kt/V, categories
      • Single-pool Kt/V, continuous
      • Urea reduction ratio >=65%
      • Ultrafiltration rate, categories
      • Ultrafiltration rate, continuous
    • Mineral and Bone Disorder
      • IV vitamin D analog use
        • Use in last 1 month
        • Use in last 3 months
        • IV vitamin D type
        • Use with cinacalcet
      • Weekly IV vitamin D analog dose received
        • 30 day average, categories
        • 30 day average, continuous
        • 90 day average, categories
        • 90 day average, continuous
      • Oral vitamin D use, last 3 months
      • Vitamin D analog use
        • Use in last 3 months
        • Vitamin D type
        • Route of administration
      • Calcimimetics use
        • Cinacalcet use, last 1 month
        • Cinacalcet use, last 3 months
        • Cinacalcet use with vitamin D
      • Serum calcium (most recent)
        • Albumin-corrected, categories
        • Albumin-corrected, continuous
        • Total, categories
        • Total, continuous
      • Serum calcium (3 month average)
        • Albumin-corrected, categories
        • Albumin-corrected, continuous
        • Total, categories
        • Total, continuous
      • Serum phosphorus (most recent)
        • Categories
        • Continuous
      • Serum phosphorus (3 month average)
        • Categories
        • Continuous
      • Phosphate binder use
        • Use in last 1 month
        • Use in last 3 months
        • Phosphate binder type
      • Serum PTH (most recent)
        • Categories
        • Continuous
      • Serum PTH (3 month average)
        • Categories
        • Continuous
      • PTH measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • MBD control
        • Number of MBD markers out of range
        • Combinations, 2 MBD markers out of range
    • Nutrition
      • Serum albumin (most recent), categories
      • Serum albumin (most recent), continuous
      • Serum albumin (3 month average), categories
      • Serum albumin (3 month average), continuous
      • Serum creatinine (most recent), categories
      • Serum creatinine (most recent), continuous
      • Serum creatinine (3 month average), categories
      • Serum creatinine (3 month average), continuous
      • Normalized PCR, categories
      • Normalized PCR, continuous
    • Vascular Access
      • Vascular access in use
  • Facility setting
    • Demographics
      • Age, categories
      • Age, continuous
      • Time on dialysis, categories
      • Time on dialysis, continuous
      • Gender
      • Race
      • Ethnicity
      • Body-mass index, categories
      • Body-mass index, continuous
    • Diabetes/Cardiovascular
      • HbA1c (most recent)
        • Categories
        • Continuous
      • HbA1c (3 month average)
        • Categories
        • Continuous
      • HbA1c measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • Pre-dialysis systolic blood pressure, categories
      • Pre-dialysis systolic blood pressure, continuous
      • Aspirin use
      • Beta blocker use
      • Calcium channel blocker use
      • Renin-angiotensin system (RAS) inhibitor use
      • Renin-angiotensin system (RAS) inhibitor combination
      • Statin use
    • Anemia
      • Hemoglobin (most recent)
        • All patients, categories
        • All patients, continuous
        • ESA-treated pts, categories
        • ESA-treated pts, continuous
      • Hemoglobin (3 month average)
        • All patients, categories
        • All patients, continuous
        • ESA-treated pts, categories
        • ESA-treated pts, continuous
      • Erythropoiesis Stimulating Agent (ESA) use
        • Use in last 1 month
        • Use in last 3 months
        • Route of administration
        • ESA type
      • Weekly IV epoetin dose received
        • 30 day average, categories
        • 30 day average, continuous
        • 90 day average, categories
        • 90 day average, continuous
      • IV iron use
        • Use in last 1 month
        • Use in last 3 months
        • IV iron type
      • Monthly IV iron dose received
        • 30 day average, categories
        • 30 day average, continuous
        • 90 day average, categories
        • 90 day average, continuous
      • Serum ferritin (most recent)
        • Categories
        • Continuous
      • Serum ferritin (3 month average)
        • Categories
        • Continuous
      • Ferritin measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • Transferrin saturation (most recent)
        • Categories
        • Continuous
      • Transferrin saturation (3 month average)
        • Categories
        • Continuous
    • Potassium
      • Serum potassium (most recent)
        • Categories
        • Continuous
      • Serum potassium (3 month average)
        • Categories
        • Continuous
      • Serum potassium measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • Potassium binder use
    • Dialysis Prescription and Dose
      • Achieved dialysis session length, categories
      • Achieved dialysis session length, continuous
      • Intra-dialytic weight loss (%)
      • Prescribed blood flow rate, categories
      • Prescribed blood flow rate, continuous
      • Prescribed dialysis sessions per week
      • Single-pool Kt/V, categories
      • Single-pool Kt/V, continuous
      • Urea reduction ratio >=65%
      • Ultrafiltration rate, categories
      • Ultrafiltration rate, continuous
    • Mineral and Bone Disorder
      • IV vitamin D analog use
        • Use in last 1 month
        • Use in last 3 months
        • IV vitamin D type
        • Use with cinacalcet
      • Weekly IV vitamin D analog dose received
        • 30 day average, categories
        • 30 day average, continuous
        • 90 day average, categories
        • 90 day average, continuous
      • Oral vitamin D use, last 3 months
      • Vitamin D analog use
        • Use in last 3 months
        • Vitamin D type
        • Route of administration
      • Calcimimetics use
        • Cinacalcet use, last 1 month
        • Cinacalcet use, last 3 months
        • Cinacalcet use with vitamin D
      • Serum calcium (most recent)
        • Albumin-corrected, categories
        • Albumin-corrected, continuous
        • Total, categories
        • Total, continuous
      • Serum calcium (3 month average)
        • Albumin-corrected, categories
        • Albumin-corrected, continuous
        • Total, categories
        • Total, continuous
      • Serum phosphorus (most recent)
        • Categories
        • Continuous
      • Serum phosphorus (3 month average)
        • Categories
        • Continuous
      • Phosphate binder use
        • Use in last 1 month
        • Use in last 3 months
        • Phosphate binder type
      • Serum PTH (most recent)
        • Categories
        • Continuous
      • Serum PTH (3 month average)
        • Categories
        • Continuous
      • PTH measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • MBD control
        • Number of MBD markers out of range
        • Combinations, 2 MBD markers out of range
    • Nutrition
      • Serum albumin (most recent), categories
      • Serum albumin (most recent), continuous
      • Serum albumin (3 month average), categories
      • Serum albumin (3 month average), continuous
      • Serum creatinine (most recent), categories
      • Serum creatinine (most recent), continuous
      • Serum creatinine (3 month average), categories
      • Serum creatinine (3 month average), continuous
      • Normalized PCR, categories
      • Normalized PCR, continuous
    • Vascular Access
      • Vascular access in use
  • Facility profit status
    • Demographics
      • Age, categories
      • Age, continuous
      • Time on dialysis, categories
      • Time on dialysis, continuous
      • Gender
      • Race
      • Ethnicity
      • Body-mass index, categories
      • Body-mass index, continuous
    • Diabetes/Cardiovascular
      • HbA1c (most recent)
        • Categories
        • Continuous
      • HbA1c (3 month average)
        • Categories
        • Continuous
      • HbA1c measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • Pre-dialysis systolic blood pressure, categories
      • Pre-dialysis systolic blood pressure, continuous
      • Aspirin use
      • Beta blocker use
      • Calcium channel blocker use
      • Renin-angiotensin system (RAS) inhibitor use
      • Renin-angiotensin system (RAS) inhibitor combination
      • Statin use
    • Anemia
      • Hemoglobin (most recent)
        • All patients, categories
        • All patients, continuous
        • ESA-treated pts, categories
        • ESA-treated pts, continuous
      • Hemoglobin (3 month average)
        • All patients, categories
        • All patients, continuous
        • ESA-treated pts, categories
        • ESA-treated pts, continuous
      • Erythropoiesis Stimulating Agent (ESA) use
        • Use in last 1 month
        • Use in last 3 months
        • Route of administration
        • ESA type
      • Weekly IV epoetin dose received
        • 30 day average, categories
        • 30 day average, continuous
        • 90 day average, categories
        • 90 day average, continuous
      • IV iron use
        • Use in last 1 month
        • Use in last 3 months
        • IV iron type
      • Monthly IV iron dose received
        • 30 day average, categories
        • 30 day average, continuous
        • 90 day average, categories
        • 90 day average, continuous
      • Serum ferritin (most recent)
        • Categories
        • Continuous
      • Serum ferritin (3 month average)
        • Categories
        • Continuous
      • Ferritin measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • Transferrin saturation (most recent)
        • Categories
        • Continuous
      • Transferrin saturation (3 month average)
        • Categories
        • Continuous
    • Potassium
      • Serum potassium (most recent)
        • Categories
        • Continuous
      • Serum potassium (3 month average)
        • Categories
        • Continuous
      • Serum potassium measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • Potassium binder use
    • Dialysis Prescription and Dose
      • Achieved dialysis session length, categories
      • Achieved dialysis session length, continuous
      • Intra-dialytic weight loss (%)
      • Prescribed blood flow rate, categories
      • Prescribed blood flow rate, continuous
      • Prescribed dialysis sessions per week
      • Single-pool Kt/V, categories
      • Single-pool Kt/V, continuous
      • Urea reduction ratio >=65%
      • Ultrafiltration rate, categories
      • Ultrafiltration rate, continuous
    • Mineral and Bone Disorder
      • IV vitamin D analog use
        • Use in last 1 month
        • Use in last 3 months
        • IV vitamin D type
        • Use with cinacalcet
      • Weekly IV vitamin D analog dose received
        • 30 day average, categories
        • 30 day average, continuous
        • 90 day average, categories
        • 90 day average, continuous
      • Oral vitamin D use, last 3 months
      • Vitamin D analog use
        • Use in last 3 months
        • Vitamin D type
        • Route of administration
      • Calcimimetics use
        • Cinacalcet use, last 1 month
        • Cinacalcet use, last 3 months
        • Cinacalcet use with vitamin D
      • Serum calcium (most recent)
        • Albumin-corrected, categories
        • Albumin-corrected, continuous
        • Total, categories
        • Total, continuous
      • Serum calcium (3 month average)
        • Albumin-corrected, categories
        • Albumin-corrected, continuous
        • Total, categories
        • Total, continuous
      • Serum phosphorus (most recent)
        • Categories
        • Continuous
      • Serum phosphorus (3 month average)
        • Categories
        • Continuous
      • Phosphate binder use
        • Use in last 1 month
        • Use in last 3 months
        • Phosphate binder type
      • Serum PTH (most recent)
        • Categories
        • Continuous
      • Serum PTH (3 month average)
        • Categories
        • Continuous
      • PTH measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • MBD control
        • Number of MBD markers out of range
        • Combinations, 2 MBD markers out of range
    • Nutrition
      • Serum albumin (most recent), categories
      • Serum albumin (most recent), continuous
      • Serum albumin (3 month average), categories
      • Serum albumin (3 month average), continuous
      • Serum creatinine (most recent), categories
      • Serum creatinine (most recent), continuous
      • Serum creatinine (3 month average), categories
      • Serum creatinine (3 month average), continuous
      • Normalized PCR, categories
      • Normalized PCR, continuous
    • Vascular Access
      • Vascular access in use
  • Geographic region
    • Demographics
      • Age, categories
      • Age, continuous
      • Time on dialysis, categories
      • Time on dialysis, continuous
      • Gender
      • Race
      • Ethnicity
      • Body-mass index, categories
      • Body-mass index, continuous
    • Diabetes/Cardiovascular
      • HbA1c (most recent)
        • Categories
        • Continuous
      • HbA1c (3 month average)
        • Categories
        • Continuous
      • HbA1c measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • Pre-dialysis systolic blood pressure, categories
      • Pre-dialysis systolic blood pressure, continuous
      • Aspirin use
      • Beta blocker use
      • Calcium channel blocker use
      • Renin-angiotensin system (RAS) inhibitor use
      • Renin-angiotensin system (RAS) inhibitor combination
      • Statin use
    • Anemia
      • Hemoglobin (most recent)
        • All patients, categories
        • All patients, continuous
        • ESA-treated pts, categories
        • ESA-treated pts, continuous
      • Hemoglobin (3 month average)
        • All patients, categories
        • All patients, continuous
        • ESA-treated pts, categories
        • ESA-treated pts, continuous
      • Erythropoiesis Stimulating Agent (ESA) use
        • Use in last 1 month
        • Use in last 3 months
        • Route of administration
        • ESA type
      • Weekly IV epoetin dose received
        • 30 day average, categories
        • 30 day average, continuous
        • 90 day average, categories
        • 90 day average, continuous
      • IV iron use
        • Use in last 1 month
        • Use in last 3 months
        • IV iron type
      • Monthly IV iron dose received
        • 30 day average, categories
        • 30 day average, continuous
        • 90 day average, categories
        • 90 day average, continuous
      • Serum ferritin (most recent)
        • Categories
        • Continuous
      • Serum ferritin (3 month average)
        • Categories
        • Continuous
      • Ferritin measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • Transferrin saturation (most recent)
        • Categories
        • Continuous
      • Transferrin saturation (3 month average)
        • Categories
        • Continuous
    • Potassium
      • Serum potassium (most recent)
        • Categories
        • Continuous
      • Serum potassium (3 month average)
        • Categories
        • Continuous
      • Serum potassium measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • Potassium binder use
    • Dialysis Prescription and Dose
      • Achieved dialysis session length, categories
      • Achieved dialysis session length, continuous
      • Intra-dialytic weight loss (%)
      • Prescribed blood flow rate, categories
      • Prescribed blood flow rate, continuous
      • Prescribed dialysis sessions per week
      • Single-pool Kt/V, categories
      • Single-pool Kt/V, continuous
      • Urea reduction ratio >=65%
      • Ultrafiltration rate, categories
      • Ultrafiltration rate, continuous
    • Mineral and Bone Disorder
      • IV vitamin D analog use
        • Use in last 1 month
        • Use in last 3 months
        • IV vitamin D type
        • Use with cinacalcet
      • Weekly IV vitamin D analog dose received
        • 30 day average, categories
        • 30 day average, continuous
        • 90 day average, categories
        • 90 day average, continuous
      • Oral vitamin D use, last 3 months
      • Vitamin D analog use
        • Use in last 3 months
        • Vitamin D type
        • Route of administration
      • Calcimimetics use
        • Cinacalcet use, last 1 month
        • Cinacalcet use, last 3 months
        • Cinacalcet use with vitamin D
      • Serum calcium (most recent)
        • Albumin-corrected, categories
        • Albumin-corrected, continuous
        • Total, categories
        • Total, continuous
      • Serum calcium (3 month average)
        • Albumin-corrected, categories
        • Albumin-corrected, continuous
        • Total, categories
        • Total, continuous
      • Serum phosphorus (most recent)
        • Categories
        • Continuous
      • Serum phosphorus (3 month average)
        • Categories
        • Continuous
      • Phosphate binder use
        • Use in last 1 month
        • Use in last 3 months
        • Phosphate binder type
      • Serum PTH (most recent)
        • Categories
        • Continuous
      • Serum PTH (3 month average)
        • Categories
        • Continuous
      • PTH measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • MBD control
        • Number of MBD markers out of range
        • Combinations, 2 MBD markers out of range
    • Nutrition
      • Serum albumin (most recent), categories
      • Serum albumin (most recent), continuous
      • Serum albumin (3 month average), categories
      • Serum albumin (3 month average), continuous
      • Serum creatinine (most recent), categories
      • Serum creatinine (most recent), continuous
      • Serum creatinine (3 month average), categories
      • Serum creatinine (3 month average), continuous
      • Normalized PCR, categories
      • Normalized PCR, continuous
    • Vascular Access
      • Vascular access in use
  • Race (black/non-black)
    • Demographics
      • Age, categories
      • Age, continuous
      • Time on dialysis, categories
      • Time on dialysis, continuous
      • Gender
      • Ethnicity
      • Body-mass index, categories
      • Body-mass index, continuous
    • Diabetes/Cardiovascular
      • HbA1c (most recent)
        • Categories
        • Continuous
      • HbA1c (3 month average)
        • Categories
        • Continuous
      • HbA1c measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • Pre-dialysis systolic blood pressure, categories
      • Pre-dialysis systolic blood pressure, continuous
      • Aspirin use
      • Beta blocker use
      • Calcium channel blocker use
      • Renin-angiotensin system (RAS) inhibitor use
      • Renin-angiotensin system (RAS) inhibitor combination
      • Statin use
    • Anemia
      • Hemoglobin (most recent)
        • All patients, categories
        • All patients, continuous
        • ESA-treated pts, categories
        • ESA-treated pts, continuous
      • Hemoglobin (3 month average)
        • All patients, categories
        • All patients, continuous
        • ESA-treated pts, categories
        • ESA-treated pts, continuous
      • Erythropoiesis Stimulating Agent (ESA) use
        • Use in last 1 month
        • Use in last 3 months
        • Route of administration
        • ESA type
      • Weekly IV epoetin dose received
        • 30 day average, categories
        • 30 day average, continuous
        • 90 day average, categories
        • 90 day average, continuous
      • IV iron use
        • Use in last 1 month
        • Use in last 3 months
        • IV iron type
      • Monthly IV iron dose received
        • 30 day average, categories
        • 30 day average, continuous
        • 90 day average, categories
        • 90 day average, continuous
      • Serum ferritin (most recent)
        • Categories
        • Continuous
      • Serum ferritin (3 month average)
        • Categories
        • Continuous
      • Ferritin measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • Transferrin saturation (most recent)
        • Categories
        • Continuous
      • Transferrin saturation (3 month average)
        • Categories
        • Continuous
    • Potassium
      • Serum potassium (most recent)
        • Categories
        • Continuous
      • Serum potassium (3 month average)
        • Categories
        • Continuous
      • Serum potassium measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • Potassium binder use
    • Dialysis Prescription and Dose
      • Achieved dialysis session length, categories
      • Achieved dialysis session length, continuous
      • Intra-dialytic weight loss (%)
      • Prescribed blood flow rate, categories
      • Prescribed blood flow rate, continuous
      • Prescribed dialysis sessions per week
      • Single-pool Kt/V, categories
      • Single-pool Kt/V, continuous
      • Urea reduction ratio >=65%
      • Ultrafiltration rate, categories
      • Ultrafiltration rate, continuous
    • Mineral and Bone Disorder
      • IV vitamin D analog use
        • Use in last 1 month
        • Use in last 3 months
        • IV vitamin D type
        • Use with cinacalcet
      • Weekly IV vitamin D analog dose received
        • 30 day average, categories
        • 30 day average, continuous
        • 90 day average, categories
        • 90 day average, continuous
      • Oral vitamin D use, last 3 months
      • Vitamin D analog use
        • Use in last 3 months
        • Vitamin D type
        • Route of administration
      • Calcimimetics use
        • Cinacalcet use, last 1 month
        • Cinacalcet use, last 3 months
        • Cinacalcet use with vitamin D
      • Serum calcium (most recent)
        • Albumin-corrected, categories
        • Albumin-corrected, continuous
        • Total, categories
        • Total, continuous
      • Serum calcium (3 month average)
        • Albumin-corrected, categories
        • Albumin-corrected, continuous
        • Total, categories
        • Total, continuous
      • Serum phosphorus (most recent)
        • Categories
        • Continuous
      • Serum phosphorus (3 month average)
        • Categories
        • Continuous
      • Phosphate binder use
        • Use in last 1 month
        • Use in last 3 months
        • Phosphate binder type
      • Serum PTH (most recent)
        • Categories
        • Continuous
      • Serum PTH (3 month average)
        • Categories
        • Continuous
      • PTH measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • MBD control
        • Number of MBD markers out of range
        • Combinations, 2 MBD markers out of range
    • Nutrition
      • Serum albumin (most recent), categories
      • Serum albumin (most recent), continuous
      • Serum albumin (3 month average), categories
      • Serum albumin (3 month average), continuous
      • Serum creatinine (most recent), categories
      • Serum creatinine (most recent), continuous
      • Serum creatinine (3 month average), categories
      • Serum creatinine (3 month average), continuous
      • Normalized PCR, categories
      • Normalized PCR, continuous
    • Vascular Access
      • Vascular access in use
  • Dialysis Organization (DO) Size
    • Demographics
      • Age, categories
      • Age, continuous
      • Time on dialysis, categories
      • Time on dialysis, continuous
      • Gender
      • Race
      • Ethnicity
      • Body-mass index, categories
      • Body-mass index, continuous
    • Diabetes/Cardiovascular
      • HbA1c (most recent)
        • Categories
        • Continuous
      • HbA1c (3 month average)
        • Categories
        • Continuous
      • HbA1c measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • Pre-dialysis systolic blood pressure, categories
      • Pre-dialysis systolic blood pressure, continuous
      • Aspirin use
      • Beta blocker use
      • Calcium channel blocker use
      • Renin-angiotensin system (RAS) inhibitor use
      • Renin-angiotensin system (RAS) inhibitor combination
      • Statin use
    • Anemia
      • Hemoglobin (most recent)
        • All patients, categories
        • All patients, continuous
        • ESA-treated pts, categories
        • ESA-treated pts, continuous
      • Hemoglobin (3 month average)
        • All patients, categories
        • All patients, continuous
        • ESA-treated pts, categories
        • ESA-treated pts, continuous
      • Erythropoiesis Stimulating Agent (ESA) use
        • Use in last 1 month
        • Use in last 3 months
        • Route of administration
        • ESA type
      • Weekly IV epoetin dose received
        • 30 day average, categories
        • 30 day average, continuous
        • 90 day average, categories
        • 90 day average, continuous
      • IV iron use
        • Use in last 1 month
        • Use in last 3 months
        • IV iron type
      • Monthly IV iron dose received
        • 30 day average, categories
        • 30 day average, continuous
        • 90 day average, categories
        • 90 day average, continuous
      • Serum ferritin (most recent)
        • Categories
        • Continuous
      • Serum ferritin (3 month average)
        • Categories
        • Continuous
      • Ferritin measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • Transferrin saturation (most recent)
        • Categories
        • Continuous
      • Transferrin saturation (3 month average)
        • Categories
        • Continuous
    • Potassium
      • Serum potassium (most recent)
        • Categories
        • Continuous
      • Serum potassium (3 month average)
        • Categories
        • Continuous
      • Serum potassium measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • Potassium binder use
    • Dialysis Prescription and Dose
      • Achieved dialysis session length, categories
      • Achieved dialysis session length, continuous
      • Intra-dialytic weight loss (%)
      • Prescribed blood flow rate, categories
      • Prescribed blood flow rate, continuous
      • Prescribed dialysis sessions per week
      • Single-pool Kt/V, categories
      • Single-pool Kt/V, continuous
      • Urea reduction ratio >=65%
      • Ultrafiltration rate, categories
      • Ultrafiltration rate, continuous
    • Mineral and Bone Disorder
      • IV vitamin D analog use
        • Use in last 1 month
        • Use in last 3 months
        • IV vitamin D type
        • Use with cinacalcet
      • Weekly IV vitamin D analog dose received
        • 30 day average, categories
        • 30 day average, continuous
        • 90 day average, categories
        • 90 day average, continuous
      • Oral vitamin D use, last 3 months
      • Vitamin D analog use
        • Use in last 3 months
        • Vitamin D type
        • Route of administration
      • Calcimimetics use
        • Cinacalcet use, last 1 month
        • Cinacalcet use, last 3 months
        • Cinacalcet use with vitamin D
      • Serum calcium (most recent)
        • Albumin-corrected, categories
        • Albumin-corrected, continuous
        • Total, categories
        • Total, continuous
      • Serum calcium (3 month average)
        • Albumin-corrected, categories
        • Albumin-corrected, continuous
        • Total, categories
        • Total, continuous
      • Serum phosphorus (most recent)
        • Categories
        • Continuous
      • Serum phosphorus (3 month average)
        • Categories
        • Continuous
      • Phosphate binder use
        • Use in last 1 month
        • Use in last 3 months
        • Phosphate binder type
      • Serum PTH (most recent)
        • Categories
        • Continuous
      • Serum PTH (3 month average)
        • Categories
        • Continuous
      • PTH measurement
        • Measurement in last 1 month
        • Measurement in last 3 months
      • MBD control
        • Number of MBD markers out of range
        • Combinations, 2 MBD markers out of range
    • Nutrition
      • Serum albumin (most recent), categories
      • Serum albumin (most recent), continuous
      • Serum albumin (3 month average), categories
      • Serum albumin (3 month average), continuous
      • Serum creatinine (most recent), categories
      • Serum creatinine (most recent), continuous
      • Serum creatinine (3 month average), categories
      • Serum creatinine (3 month average), continuous
      • Normalized PCR, categories
      • Normalized PCR, continuous
    • Vascular Access
      • Vascular access in use
Download Quality of Life Data
Browse Graphics

Share





Sign up for DPM updates
Copyright © 2019, Arbor Research Collaborative for Health.  |  Citation Advice  |   |  Privacy Policy  |  Feedback?

Citation Advice

We welcome you to use the data and graphics displayed on this website. We value the distribution of knowledge for the benefit of patient care and renal research. Please use the following citation as applicable: [Title/description of webpage]. The DOPPS Practice Monitor. [URL/Address of webpage being cited]. Accessed [insert date here]. Modifying DOPPS Practice Monitor data, tables, or graphics in any form is not permitted without prior approval from the DOPPS coordinating center staff at Arbor Research. You may contact us at DOPPS@ArborResearch.org

Quality of Life Data Download

Complete the form below to download a spreadsheet of patient-reported quality of life summary data and graphs from the DPM sample